Actively Recruiting
Immune Responses to Dengue and Sepsis
Led by Institut Pasteur du Cambodge · Updated on 2025-06-27
240
Participants Needed
3
Research Sites
78 weeks
Total Duration
On this page
Sponsors
I
Institut Pasteur du Cambodge
Lead Sponsor
N
National Institute of Allergy and Infectious Diseases (NIAID)
Collaborating Sponsor
AI-Summary
What this Trial Is About
The goal of this research study is to help the investigators better understand serious dengue disease. The investigators will collect clinical information and up to four blood samples from participants with dengue, sepsis, or healthy people. The investigators will perform multiple analyses on the blood samples and compare results between dengue patients and those with sepsis and healthy people.
CONDITIONS
Official Title
Immune Responses to Dengue and Sepsis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients presenting with dengue-like symptoms for up to 72 hours, including fever over 38 0C plus at least two symptoms such as headache, retro-orbital pain, muscle or joint pain, rash, bleeding, nausea, vomiting, lethargy, abdominal pain, or liver enlargement
- Patients admitted for less than 48 hours with a primary diagnosis of sepsis, blood cultures ordered, and receiving empiric antibiotics for suspected bacterial infection
- Healthy participants with no chronic illnesses, no regular medications, no fever in the past 28 days, and no dengue or bacterial infection diagnosis or treatment in the past 6 months
You will not qualify if you...
- Children under 2 years old
- Pregnant individuals, those pregnant within the last 90 days, or currently breastfeeding
- Individuals who do not provide informed consent
- People with severe or chronic diseases such as autoimmune disorders, immunodeficiency, blood disorders, heart disease, diabetes, cancer, HIV, or chronic liver or kidney failure
- Those who have taken immunosuppressants or immune-modifying drugs for more than 14 days in the past 6 months (except inhaled or topical steroids)
- Chronic use of NSAIDs including aspirin for more than 2 weeks in the past 6 months or any use within 7 days before sampling (except low-dose aspirin up to 250 mg daily)
- Any other condition that might interfere with study participation as judged by the investigator
- Expected death within the next 48 hours
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Kampong Speu District Referral Hospital
Kampong Speu, Cambodia
Actively Recruiting
2
International Center of Excellence in Research Cambodia
Phnom Penh, Cambodia
Actively Recruiting
3
Preah Kossamak Hospital
Phnom Penh, Cambodia
Actively Recruiting
Research Team
C
Chanthap Lon, MD
CONTACT
C
Camila D Odio, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here